8/16/2023 0 Comments Roche diagnostics productsIn August, Roche launched the Digital LightCycler System, a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient’s cancer, genetic disease, or infection. This panel measures two blood-based biomarkers, called pTau 181 and ApoE4. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its Elecsys Amyloid Plasma Panel, which enables Alzheimer’s disease to be detected earlier. Pathology Lab products, with a focus on tissue biopsies and companion diagnostics that support specific therapy decisions for each patient, saw growth mainly in advanced staining and the companion diagnostics businesses.Īmong the highlights of the third quarter, Roche noted in July, the U.S. and in major European markets, was partly offset by higher demand in emerging markets. Excluding this effect, sales remained stable, Roche said, and the continued contraction of the blood glucose monitoring market, mainly in the U.S. Declines were partly offset by growth in the base business across the portfolio and by the GenMark and TIB Molbiol businesses, which Roche acquired in 2021.ĭiabetes Care products for integrated personalized diabetes management for people with diabetes and healthcare professionals fell, due to expenses associated with the resolution of a rebate dispute in 2021. Molecular Lab products for pathogen detection and monitoring, donor screening, sexual health, and genomics declined, mainly due to lower COVID-19-related sales in the North America and EMEA regions.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |